Target Therapy, Medical Resource Utilization and Cost Effectiveness Analysis of Non-Small Cell Lung Cancer in Taiwan
碩士 === 高雄醫學大學 === 醫務管理學研究所碩士在職專班 === 98 === The National Health Insurance (NHI) has included drugs used for target therapy to treat Non-Small Cell Lung Cancer (NSCLC) such as Gefitinib (Iressa) and Erlotinib (Tarceva) in the reimbursement list since 2004. However, research evaluating what should be...
| Main Authors: | , |
|---|---|
| Other Authors: | |
| Format: | Others |
| Language: | zh-TW |
| Published: |
2010
|
| Online Access: | http://ndltd.ncl.edu.tw/handle/25329764623498516915 |